Αποτελέσματα Αναζήτησης
Diffuse midline glioma (DMG), formerly called diffuse intrinsic pontine glioma (DIPG), is a high-grade malignant pediatric brain tumor with a near-zero survival rate. To date, only radiation therapy provides marginal survival benefit; however, the median survival time remains less than a year.
21 Ιουν 2024 · Diffuse midline glioma (DMG), H3 K27M-mutant is a type of diffuse high-grade glioma that occurs in the brain midline carrying an extremely poor prognosis under the best efforts of surgery, radiation, and other therapies.
1 Ιουν 2023 · Diffuse midline glioma (DMG) is the leading cause of brain tumor-related deaths in children. DMG typically presents with variable neurologic symptoms between ages 3 and 10. Currently, radiation remains the standard therapy for DMG to halt progression and reduce tumor bulk to minimize symptoms.
Fractionated external beam radiotherapy (RT), the standard of care for DMG, has only been successful in providing limited disease control or improving symptoms and confers a survival benefit of approximately 3 months. In the absence of standard RT, the median survival is 6 months [8].
As penetration of systemic therapy through the blood-brain barrier (BBB) is a significant limitation to the success of DMG therapies, we explore focused ultrasound (FUS) and convection-enhanced delivery (CED) to overcome the BBB and maximize therapeutic efficacy.
3 Νοε 2023 · Diffuse midline gliomas (DMGs) generally carry a poor prognosis, occur during childhood, and involve midline structures of the central nervous system, including the thalamus, pons, and spinal cord. To date, irradiation has been shown to be the only beneficial treatment for DMG.
7 Φεβ 2022 · This clinical trial will continue to treat patients with H3K27M + DIPG and spinal DMG using GD2-CAR T cell therapy to determine optimal dose, route and schedule, and to determine efficacy.
